KITE 753 Trials Placed on Partial Clinical Hold
Gilead disclosed on its 29 October earnings call that PALISADES-1 and PALISADES-2, studying the bicistronic CD19/CD20 CAR-T KITE-753 in relapsed or refractory diffuse large B-cell lymphoma, are on partial clinical hold while it investigates…
